The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

December 06, 2021

William G. Wierda, MD, PhD, discussed the results of the phase 2 CAPTIVATE trial and the phase 1/2 TRANSCEND CLL 004 trial, and looked ahead to what the future holds for MRD in patients with CLL.

December 03, 2021

Kanwal Raghav, MBBS, MD, discusses the safety profiles of regorafenib and trifluridine/tipiracil, and selecting between the agents for the treatment of patients with colorectal cancer.

December 02, 2021

James P. Allison, PhD, discusses his experience with the urgency of drug development in oncology. 

December 01, 2021

Joyce L. Neumann, PhD, APRN, AOCN, BMTCN, FAAN, discusses tapering steroids for patients with chronic graft-vs-host disease.

November 30, 2021

James P. Allison, PhD, discusses the impact of immunotherapy on patients with cancer. 

November 30, 2021

James P. Allison, PhD, discusses the development of ipilimumab.

November 29, 2021

James P. Allison, PhD, discusses his early career at The University of Texas MD Anderson Cancer Center.

November 29, 2021

James P. Allison, PhD, discusses his research on reverse translation in cancer. 

November 23, 2021

The combination of enasidenib plus azacitidine was well tolerated and induced significantly improved response rates compared with azacitidine alone in patients with newly diagnosed, IDH2-mutant acute myeloid leukemia.

November 16, 2021

Daniel M. Halperin, MD, discusses the efficacy and safety results of the phase 1/2a Protocol PEN-221-001 trial in advanced gastrointestinal mid-gut neuroendocrine tumors.

November 15, 2021

Xiuning Le, MD, PhD, discusses the emergence of antibody-drug conjugates in non–small cell lung cancer.

November 08, 2021

Bilal A. Siddiqui, MD, discusses the potential for novel imaging in patients with nonmetastatic castration-resistant prostate cancer.

November 05, 2021

Significant progress with rapidly evolving therapies, including blinatumomab, inotuzumab ozogamicin, and CAR T-cell therapy, has been made to extend the median overall survival and improve outcomes for patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

November 03, 2021

Newer modalities are exploring ways to provide more specificity on the value of minimal residual disease negativity in acute myeloid leukemia, since currently there is little definitive action that can be taken with the marker in clinical practice, according to Naval Daver, MD.

November 02, 2021

John V. Heymach, MD, PhD, discusses the background of the Impower010 trial, the benefit for patients with PD-L1 levels of at least 1%, and the exciting direction adjuvant therapy in NSCLC is heading.

November 01, 2021

Sequential radiotherapy demonstrated preliminary efficacy and safety as a potential alternative to systemic therapy in patients with oligometastatic renal cell carcinoma.

October 27, 2021

The ATR inhibitor RP-3500 demonstrated a manageable safety profile and promising early antitumor efficacy in patients whose tumors harbor select genomic alterations when administered at doses of 100 mg or more.

October 25, 2021

William G. Wierda, MD, PhD, discusses future research directions with minimal residual disease testing in patients with chronic lymphocytic leukemia.

October 21, 2021

William G. Wierda, MD, PhD, discusses efforts to examine fixed-duration treatment strategies in patients with chronic lymphocytic leukemia.

October 21, 2021

Sumit K. Subudhi, MD, PhD, discusses the integration of antiandrogen agents in metastatic hormone-sensitive prostate cancer.